JP2015520769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520769A5 JP2015520769A5 JP2015514535A JP2015514535A JP2015520769A5 JP 2015520769 A5 JP2015520769 A5 JP 2015520769A5 JP 2015514535 A JP2015514535 A JP 2015514535A JP 2015514535 A JP2015514535 A JP 2015514535A JP 2015520769 A5 JP2015520769 A5 JP 2015520769A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- substituents
- independently selected
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims description 112
- 125000000217 alkyl group Chemical group 0.000 claims description 109
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 47
- 229910052717 sulfur Inorganic materials 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 37
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 36
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- 125000001624 naphthyl group Chemical group 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 30
- 125000005842 heteroatoms Chemical group 0.000 claims description 30
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 125000004429 atoms Chemical group 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 229960001663 sulfanilamide Drugs 0.000 claims description 18
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 18
- 150000003573 thiols Chemical class 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 13
- 230000000495 immunoinflammatory Effects 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 206010011401 Crohn's disease Diseases 0.000 claims description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 7
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 206010072736 Rheumatic disease Diseases 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 6
- 201000004681 psoriasis Diseases 0.000 claims description 6
- 201000006704 ulcerative colitis Diseases 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000240 adjuvant Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 6
- 125000001326 naphthylalkyl group Chemical group 0.000 description 6
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 3
- 0 CC(CC(c1ccccc1)=O)=C(C=CC=C1)C1=CC(SCCN(C)C)=** Chemical compound CC(CC(c1ccccc1)=O)=C(C=CC=C1)C1=CC(SCCN(C)C)=** 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- XDZBDLYXHMKEPU-UHFFFAOYSA-N Fc1cc(NCc2nc(OCCN3CCCCC3)cc3c2cccc3)cc(F)c1 Chemical compound Fc1cc(NCc2nc(OCCN3CCCCC3)cc3c2cccc3)cc(F)c1 XDZBDLYXHMKEPU-UHFFFAOYSA-N 0.000 description 1
- SOVOWYHTJTWTFL-UHFFFAOYSA-N NCCCc1cc(cccc2)c2c(NC=O)n1 Chemical compound NCCCc1cc(cccc2)c2c(NC=O)n1 SOVOWYHTJTWTFL-UHFFFAOYSA-N 0.000 description 1
- YOEBCMBOBHLGML-UHFFFAOYSA-N O=C(Cc1nc(SCCN2CCCCC2)cc2c1cccc2)c1cc(F)cc(F)c1 Chemical compound O=C(Cc1nc(SCCN2CCCCC2)cc2c1cccc2)c1cc(F)cc(F)c1 YOEBCMBOBHLGML-UHFFFAOYSA-N 0.000 description 1
- ASZRNYIGTQIFJA-UHFFFAOYSA-N O=C(c1ccccc1)Nc1nc(CCCN2CCCC2)cc2c1cccc2 Chemical compound O=C(c1ccccc1)Nc1nc(CCCN2CCCC2)cc2c1cccc2 ASZRNYIGTQIFJA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654385P | 2012-06-01 | 2012-06-01 | |
| US61/654,385 | 2012-06-01 | ||
| PCT/EP2013/061330 WO2013178816A1 (en) | 2012-06-01 | 2013-05-31 | Heterocycles capable of modulating t-cell responses, and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520769A JP2015520769A (ja) | 2015-07-23 |
| JP2015520769A5 true JP2015520769A5 (US07714131-20100511-C00001.png) | 2016-07-21 |
| JP6167173B2 JP6167173B2 (ja) | 2017-07-19 |
Family
ID=48538006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514535A Expired - Fee Related JP6167173B2 (ja) | 2012-06-01 | 2013-05-31 | Ｔ細胞受容体を調節することができる複素環およびそれを使用するための方法 |
Country Status (19)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| JP5715070B2 (ja) | 2009-02-16 | 2015-05-07 | ノグラ ファーマ リミテッド | アルキルアミド化合物およびその使用 |
| CN104254327A (zh) | 2012-02-09 | 2014-12-31 | 诺格拉制药有限公司 | 治疗纤维化的方法 |
| WO2013156413A1 (en) | 2012-04-18 | 2013-10-24 | Nogra Pharma Limited | Methods of treating lactose intolerance |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| US9160671B2 (en) | 2012-12-03 | 2015-10-13 | Hewlett-Packard Development Company, L.P. | Ingress traffic classification and prioritization with dynamic load balancing |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| CA2959208C (en) | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
| US9894013B2 (en) | 2015-02-03 | 2018-02-13 | Avago Technologies General Ip (Singapore) Pte. Ltd. | Early queueing network device |
| US10567273B2 (en) * | 2015-03-27 | 2020-02-18 | Cavium, Llc | Method and apparatus for bypass routing of multicast data packets and avoiding replication to reduce overall switch latency |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| EP4075703A1 (en) * | 2016-02-03 | 2022-10-19 | Interdigital Patent Holdings, Inc. | Methods, systems and apparatus for scheduling of subframes and hybrid automatic repeat request (harq) feedback |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| EP3468953B1 (en) | 2016-06-13 | 2024-05-22 | GlaxoSmithKline Intellectual Property Development Limited | Substituted pyridines as inhibitors of dnmt1 |
| WO2018009468A1 (en) | 2016-07-05 | 2018-01-11 | Idac Holdings, Inc. | Latency reduction by fast forward in multi-hop communication systems |
| WO2018089967A1 (en) | 2016-11-14 | 2018-05-17 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
| RS62959B1 (sr) | 2017-01-11 | 2022-03-31 | Alkermes Inc | Biciklični inhibitori histon-deacetilaze |
| ES2906078T3 (es) | 2017-01-23 | 2022-04-13 | Cadent Therapeutics Inc | Moduladores del canal de potasio |
| CN110366841B (zh) | 2017-03-06 | 2021-09-17 | 三菱电机株式会社 | 传送装置、传送方法和传送系统 |
| MD3664802T2 (ro) | 2017-08-07 | 2022-07-31 | Alkermes Inc | Inhibitori biciclici ai deacetilazei histonei |
| IL272838B2 (en) | 2017-10-06 | 2023-09-01 | Forma Therapeutics Inc | Peptidase-specific ubiquitin inhibition 30 |
| US10476815B2 (en) * | 2017-12-11 | 2019-11-12 | Ciena Corporation | Adaptive communication network with cross-point switches |
| SG11202011299PA (en) | 2018-05-17 | 2020-12-30 | Forma Therapeutics Inc | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| JP6977668B2 (ja) * | 2018-06-04 | 2021-12-08 | 日本電信電話株式会社 | 測定システム、及び測定方法 |
| PE20211053A1 (es) | 2018-10-05 | 2021-06-07 | Forma Therapeutics Inc | Inhibicion de la proteasa 30 especifica de la ubiquitina (usp30) |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US11993586B2 (en) | 2018-10-22 | 2024-05-28 | Novartis Ag | Crystalline forms of potassium channel modulators |
| US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| JP7214882B2 (ja) | 2018-10-30 | 2023-01-30 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体 |
| CA3115830C (en) | 2018-10-30 | 2023-09-12 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
| CN113825739A (zh) | 2019-02-08 | 2021-12-21 | 诺格拉制药有限公司 | 制备3-(4’-氨基苯基)-2-甲氧基丙酸及其类似物和中间体的方法 |
| JP2022539208A (ja) | 2019-07-03 | 2022-09-07 | スミトモ ファーマ オンコロジー， インコーポレイテッド | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
| JP2023526332A (ja) | 2020-05-15 | 2023-06-21 | アルゲン バイオテクノロジーズ，インク． | 特定の化学組成物およびその使用方法 |
| IL298324A (en) | 2020-06-10 | 2023-01-01 | Aligos Therapeutics Inc | Antiviral compounds for the treatment of coronavirus, picornavirus and novovirus infections |
| US20240109865A1 (en) | 2020-12-30 | 2024-04-04 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
| EP4366831A1 (en) | 2021-07-09 | 2024-05-15 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12065428B2 (en) | 2021-09-17 | 2024-08-20 | Aligos Therapeutics, Inc. | Anti-viral compounds |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1109180B (de) | 1953-04-16 | 1961-06-22 | Schering Ag | Verfahren zur Herstellung von Chinazolinen |
| SU1069385A1 (ru) | 1982-05-07 | 1990-11-15 | Научно-исследовательский институт фармакологии АМН СССР | Бромид 2-амино-3-(1-адамантилкарбонилметил)-1-( @ -пиперидино-этил)-бензимидазоли , обладающий способностью угнетать иммунитет |
| GB9016800D0 (en) | 1990-07-31 | 1990-09-12 | Shell Int Research | Tetrahydropyrimidine derivatives |
| GB2323842A (en) * | 1997-04-04 | 1998-10-07 | Ferring Bv | Pyridine derivatives |
| KR20010042840A (ko) | 1998-04-20 | 2001-05-25 | 스타르크, 카르크 | 신규한 치환된 아미드, 그의 제조 및 그의 용도 |
| JO2308B1 (en) * | 1999-05-31 | 2005-09-12 | اف. هوفمان- لاروش أيه جي | Derivatives of phenylpyrmidine |
| GB9915437D0 (en) * | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| CA2292828A1 (en) * | 1999-12-22 | 2001-06-22 | Nortel Networks Corporation | Method and apparatus for traffic flow control in data switches |
| US6765866B1 (en) * | 2000-02-29 | 2004-07-20 | Mosaid Technologies, Inc. | Link aggregation |
| US7260104B2 (en) * | 2001-12-19 | 2007-08-21 | Computer Network Technology Corporation | Deferred queuing in a buffered switch |
| AU2002334205B2 (en) * | 2001-10-26 | 2007-07-05 | Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase |
| US7868028B2 (en) | 2002-06-17 | 2011-01-11 | Fred Drasner | Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| CA2519677A1 (en) * | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
| DE602004022819D1 (de) | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| EA010974B1 (ru) * | 2004-05-26 | 2008-12-30 | Янссен Фармацевтика Н.В. | Меркаптоимидазолы в качестве антагонистов рецепторов ccr2 |
| US7602712B2 (en) * | 2004-06-08 | 2009-10-13 | Sun Microsystems, Inc. | Switch method and apparatus with cut-through routing for use in a communications network |
| WO2006031806A2 (en) * | 2004-09-10 | 2006-03-23 | Atherogenics, Inc. | 2-thiopyrimidinones as therapeutic agents |
| EP1861377B1 (en) | 2005-03-15 | 2010-12-29 | Pfizer, Inc. | Benzimidazolone derivatives as cb2 receptor ligands |
| CA2600832C (en) | 2005-03-31 | 2011-12-13 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hiv integrase inhibitors |
| EP2527337A1 (en) | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| WO2007024680A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| JP2009523816A (ja) | 2006-01-19 | 2009-06-25 | アボット・ラボラトリーズ | ２−イミノ−ベンズイミダゾール類 |
| JP2008013499A (ja) | 2006-07-06 | 2008-01-24 | Sankyo Co Ltd | ５−シアノニコチンアミド誘導体 |
| AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| US7843846B1 (en) * | 2006-09-18 | 2010-11-30 | Qlogic, Corporation | Method and system for processing network information |
| WO2008036244A1 (en) | 2006-09-18 | 2008-03-27 | The Burham Institute For Medical Research | Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands |
| US7847099B2 (en) | 2006-09-21 | 2010-12-07 | California Institute Of Technology | Non-metallocene organometallic complexes and related methods and systems |
| US8093246B2 (en) | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
| JP5178738B2 (ja) * | 2006-12-20 | 2013-04-10 | メルク・シャープ・アンド・ドーム・コーポレーション | 新規なｊｎｋ阻害剤 |
| ES2381452T3 (es) * | 2007-10-19 | 2012-05-28 | Boehringer Ingelheim International Gmbh | PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas |
| LT2262778T (lt) | 2008-03-07 | 2019-11-11 | Acraf | 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydant ligas, pagrįstas mcp-1, cxcr1 ir p40 raiška |
| KR101581829B1 (ko) | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
| KR101598931B1 (ko) * | 2008-03-24 | 2016-03-02 | 신닛테츠 수미킨 가가쿠 가부시키가이샤 | 유기 전계 발광 소자용 화합물 및 이것을 이용한 유기 전계 발광 소자 |
| EP2303859A4 (en) | 2008-06-20 | 2012-08-22 | Metabolex Inc | ARYL GPR119 AGONISTS AND USES THEREOF |
| RU2011101661A (ru) * | 2008-07-16 | 2012-08-27 | Астразенека Аб (Se) | Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний |
| WO2010011756A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| EP2313372B1 (en) * | 2008-08-06 | 2013-04-10 | Vertex Pharmaceuticals Incorporated | Aminopyridine kinase inhibitors |
| WO2010068806A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| CA2758614A1 (en) * | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
| TW201040162A (en) * | 2009-05-06 | 2010-11-16 | Portola Pharm Inc | Inhibitors of JAK |
| US20120172384A1 (en) * | 2009-06-18 | 2012-07-05 | Mihiro Sunose | Heterocyclylaminopyrimidines as kinase inhibitors |
| WO2011029807A1 (en) * | 2009-09-11 | 2011-03-17 | Cellzome Limited | Ortho substituted pyrimidine compounds as jak inhibitors |
| JP5674058B2 (ja) | 2009-12-28 | 2015-02-25 | ディヴェロップメント センター フォー バイオテクノロジー | ｍＴＯＲ阻害剤及びＰＩ３Ｋ阻害剤としての新規ピリミジン化合物 |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| DE102010034699A1 (de) | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| EA201490406A1 (ru) | 2011-07-29 | 2014-07-30 | Кариофарм Терапевтикс, Инк. | Модуляторы ядерного транспорта и их применение |
| WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| US20150126553A1 (en) | 2012-06-01 | 2015-05-07 | Nogra Pharma Limited | Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| RU2019131017A (ru) | 2013-10-21 | 2019-11-25 | Мерк Патент Гмбх | Соединения гетероарила в качестве ингибиторов btk и их применение |
-
2012
- 2012-08-01 US US13/564,118 patent/US9013997B2/en active Active
- 2012-09-12 US US13/611,252 patent/US9325637B2/en not_active Expired - Fee Related
-
2013
- 2013-05-31 PL PL13726006T patent/PL2861575T3/pl unknown
- 2013-05-31 SI SI201331441T patent/SI2861575T1/sl unknown
- 2013-05-31 ES ES13726006T patent/ES2726109T3/es active Active
- 2013-05-31 MX MX2014014658A patent/MX366205B/es active IP Right Grant
- 2013-05-31 HU HUE13726006A patent/HUE043201T2/hu unknown
- 2013-05-31 JP JP2015514535A patent/JP6167173B2/ja not_active Expired - Fee Related
- 2013-05-31 CN CN201380033708.0A patent/CN104619691B/zh not_active Expired - Fee Related
- 2013-05-31 AU AU2013269551A patent/AU2013269551B2/en not_active Ceased
- 2013-05-31 CA CA2874938A patent/CA2874938C/en active Active
- 2013-05-31 PT PT13726006T patent/PT2861575T/pt unknown
- 2013-05-31 LT LTEP13726006.3T patent/LT2861575T/lt unknown
- 2013-05-31 WO PCT/EP2013/061330 patent/WO2013178816A1/en active Application Filing
- 2013-05-31 KR KR1020147036727A patent/KR102181914B1/ko active IP Right Grant
- 2013-05-31 BR BR112014030050A patent/BR112014030050A2/pt not_active IP Right Cessation
- 2013-05-31 EP EP13726006.3A patent/EP2861575B1/en active Active
- 2013-05-31 US US14/404,839 patent/US10208017B2/en active Active
- 2013-05-31 DK DK13726006.3T patent/DK2861575T3/da active
-
2018
- 2018-12-21 US US16/229,687 patent/US10562883B2/en not_active Expired - Fee Related
-
2019
- 2019-04-25 HR HRP20190764 patent/HRP20190764T1/hr unknown
- 2019-05-10 CY CY20191100506T patent/CY1122203T1/el unknown
